NEW YORK, Sept. 12, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that MD Anderson Cancer Center in Houston, Texas has joined the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML). The trial is designed to establish safety and efficacy of API's drug Actimab-A in AML patients over the age of 60. Actimab-A treatment consists of the isotope Actinium 225 attached to the anti-CD33 monoclonal antibody lintuzumab (HuM195).
"This is an important milestone in the development of our drug candidate," said Jack Talley, CEO of Actinium Pharmaceuticals. "MD Anderson is a leading cancer treatment institution and treats more patients with acute myeloid leukemia than any other center in the world. We view their joining our trial as a key vote of confidence for our innovative, world class technology."
MD Anderson is the third center to sign a clinical trial agreement with Actinium Pharmaceuticals, following Memorial Sloan Kettering Cancer Center (MSKCC) in New York, NY and Fred Hutchinson Cancer Research Center (FHCRC) in Seattle, Washington.
Phase I/II multi-center Actimab study will build on the previous phase I/II Bismab-A study with a less potent bismuth-213 (Bi-213) isotope and an earlier Actimab-A phase 1 study (where only a single dose of Actimab was administered). The Phase II portion of the earlier Bismab-A study demonstrated the efficacy of API's alpha particle platform by producing a number of complete responses in difficult-to-treat relapsed, secondary and poor cytogenetics AML patients with no standard of care options available. The goal of the current study is to confirm efficacy and safety of Actimab-A using the same antibody targeting mechanism with the actinium isotope, produced by an improved method of manufacture, and to study the effect of mu
|SOURCE Actinium Pharmaceuticals, Inc.|
Copyright©2012 PR Newswire.
All rights reserved